| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.0095 | 0.9 |
| mRNA | itraconazole | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | Panobinostat | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |